Specific BRCA and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomas
F. Menghi, K. Banda, P. Kumar, R. Straub, L. Dobrolecki, I. V. Rodriguez, S. E. Yost, H. Chandok, M. R. Radke, A. S. Zhu, G. Somlo, Y. Yuan, M. T. Lewis, E. M. Swisher, E. T. Liu
This study identifies that BRCA1 promoter methylation (BRCA1meth) leads to adaptive recovery of BRCA1 expression and poorer response to platinum chemotherapy compared to BRCA mutations, while immune signals enhance response in BRCA-proficient cancers.
bioRxiv · Aug 19, 2021 · PreprintCancer Biology